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Background: Somatic copy number aberrations (CNA) are common acquired changes in 
cancer cells playing an important role in the progression of colon cancer (CRC). This study 
aimed to perform a characterization of CNA and their impact in gene expression. 
Methods: CNA were inferred from SNP array data in a series of 99 CRC. CNA events were 
calculated and used to assess the association between copy number dosage, clinical and 
molecular characteristics of the tumours, and gene expression changes. All analyses were 
adjusted for the quantity of stroma in each sample, that was inferred from gene expression 
data.  
Results: High heterogeneity among samples was observed, the proportion of altered 
genome ranged between 0.04 and 26.6%. Recurrent CNA regions with gains were frequent 
in chromosomes 7p, 8q, 13q, and 20 while 8p, 17p, and 18 cumulated loses. A significant 
positive correlation was observed between the number of somatic mutations and total CNA 
(Spearman r=0.42, P=0.006). Approximately 37% of genes located in CNA regions changed 
their level of expression, and the average partial correlation (adjusted for stromal content) 
with copy number was 0.54 (inter-quartile range 0.20 to 0.81). Altered genes showed 
enrichment in pathways relevant for colorectal cancer. Tumours classified as CMS2 and 
CMS4 by the consensus molecular subtyping showed higher frequency of CNA. Loses of 
one small region in 1p36.33, with gene CDK11B, were associated with poor prognosis. More 
than 66% of the recurrent CNA were validated in the TCGA data when analysed with the 
same procedure. Also 79% of the genes with altered expression in our data were validated in 
the TCGA. 
Conclusion: Though CNA are frequent events in MSS CRC, few focal recurrent regions 
were found. These aberrations have strong effects on gene expression and contribute to 
deregulate relevant cancer pathways. Due to the diploid nature of stromal cells, it is 




Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world and the 
second leading cause of cancer deaths in both men and women. CRC’s incidence trend is 
still increasing in most countries (Ferlay et al, 2013). At a molecular level, CRC is a complex 
disease involving different alterations (An et al, 2015). Large chromosomal aberrations have 
been described in colon tumours, with recurrent gains in chromosome arms 7p, 8q, 13q and 
20 and losses in 8p, 17p and 18 (Ashktorab et al, 2010; Brosens et al, 2011; Goossens-
Beumer et al, 2015; Meijer et al, 1998). Tsafrir et al. showed that tumour copy number 
aberrations (CNA) may lead to changes in gene expression relevant in colorectal 
carcinogenesis (Tsafrir et al, 2006). In particular, genes in amplified chromosome regions (7p, 
8q, 13q, and 20q) usually were over-expressed and genes in regions with 
chromosome losses (1p, 4, 5q, 8p, 14q, 15q, and 18) were under-expressed. These 
aberrations can lead to the silencing or amplification of tumour suppressor genes, oncogenes, 
or non-coding RNAs that modify the expression of genes. Some examples of the relevance 
of CNA in CRC are losses of chromosome 17p, which contains tumour suppressor genes 
TP53 and MAP2K4 (Han et al, 2013); and gains in 7q31 associated with WNT2 
overexpression which alters Wnt signalling activation (Wang et al, 2016).  Gains in 20q have 
been studied in more detail because they are associated with poor prognosis in CRC (Hidaka 
et al, 2000;Wang et al, 2016). This amplification is correlated with the overexpression of 
TPX2 and AURKA genes (Sillars-Hardebol et al, 2012;Wang et al, 2016) both involved in 
processes that promote colorectal adenoma to carcinoma progression, cell viability, and the 
anchorage-independent growth and invasion processes. This region also harbours C20orf24 
(20q11.23), ADRM1 (20q13.33), TCFL5 (20q13.33), PLCG1 (20q12) and TH1L (20q13.32), 
genes that have been highlighted for their importance in chromosomal instability and 
adenoma to carcinoma progression (Ali Hassan et al, 2014; Loo et al, 2013; Sokolova et al, 
2016). However, the relationship between CNA and gene expression is complex and still not 
completely defined. Also, difficulties in the methodology to define CNAs from SNP arrays 
may explain some of the heterogeneity in the results reported so far. 
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CRC tumours have been classically classified into microsatellite instable (MSI), derived from  
deficient DNA mismatch repair machinery which leads to hyper-mutated tumours, and 
microsatellite stable (MSS), also referred to as chromosomal instable tumours (CIN). MSS 
tumours often show CNA (Brosens et al, 2011; The Cancer Genome Atlas Network, 2012; 
Trautmann et al, 2006; Xie et al, 2012) and follow the classical adenoma-to-carcinoma 
progression model (Brosens et al, 2011). Recently, consensus molecular subtypes of CRC 
have been defined by means of non-supervised classification techniques using gene 
expression data (Guinney et al, 2015). This classification establishes four major subtypes 
(CMS1-4) with specific molecular characteristics. CMS1 (14% of CRC) comprises tumours 
associated to a MSI phenotype and to immune pathways activation. This subtype usually has 
the best prognosis. CMS2 (41% of CRC) is characterized by high CIN and strong WNT/MYC 
pathways activation. CMS3 (8% of CRC) show low CIN, but are generally KRAS mutant and 
have activated pathways related to energy metabolism. Finally, CMS4 (20% of CRC) show 
up-regulation of TGF-β signalling and have been associated with the worst survival and poor 
response to chemotherapy. Some controversy exists around whether tumours of CMS4 
subtype exhibit a mesenchymal phenotype or are enriched in the stromal component, since 
genes up-regulated in this subtype are mainly expressed by stromal cells rather than by 
epithelial cells (Isella et al, 2015). Indeed, this is an important issue to consider in copy 
number analysis, since the diploid nature of stromal cells amalgamated within the tumour 
bulk could mask real CNA changes in cancer epithelial cells. 
 
In this study we have performed a detailed characterization of CNA in stage II, MSS colon 
tumours, taking into account the quantity of diploid stromal cells, which was estimated for 
each tumour sample. Moreover, we have explored the relation of these aberrations with gene 
expression changes and characteristics of the tumours such as molecular subtyping and 




Patients and samples 
Tumour tissues and their paired adjacent normal mucosa from 100 stage II, MSS colon 
cancer patients have been molecularly profiled to obtain data on copy number, gene 
expression, methylation and somatic mutations (with exome sequencing in a subset of 42 
samples; Colonomics project: www.colonomics.org; NCBI BioProject PRJNA188510). All 
patients were treated with radical surgery, did not receive adjuvant therapy and have been 
followed-up a minimum of three years (Supplementary Table 1). Adjacent normal tissue was 
dissected at pathology from the proximal tumour resection margin with a minimum distance 
of 10 cm to the tumour lesion. All patients were recruited at the Bellvitge University Hospital 
(Spain) between 1998 and 2002, provided written informed consent and the hospital Ethics 
Committee approved the protocol with reference PR074/11.  
 
Copy number and gene expression data on 222 colon tumours and 22 normal adjacent 
tissues from The Cancer Genome Atlas (TCGA) repository (The Cancer Genome Atlas 
Network, 2012) were downloaded and used as a validation dataset. These tumours were 
selected because gene expression was available on the Agilent array platform, equivalent to 
our setting, that was convenient to estimate the stromal content. To use the maximum 
sample size, both colon and rectal samples and diverse stages at diagnosis were included 
(Supplementary Table 1).  
 
Copy Number Analysis 
CNA were inferred from the analysis of Affymetrix Genome-Wide Human SNP Array 6.0 
genotyping arrays (Carter, 2007; Eldai et al, 2013). This array includes probes for the 
detection of over 906,600 SNPs and an additional 946,000 non-polymorphic oligonucleotides 
for the assessment of copy number variation. The average inter-marker distance was less 
than 700 bp. Affymetrix Power Tools (Version 1.16.1) software was used (Eckel-Passow et al, 
2011), with default parameters, to assess a quantitative locus-level copy number estimate 
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(CNE) for each tumour sample, as = log  , where  was the normalized intensity 
at probe j for sample i and  was a reference intensity at probe j, typically representing the 
mean diploid signal derived from the average pool of normal mucosa samples.  
 
Segmentation 
A segmentation algorithm was applied to split the set of ordered locus-specific CNE into 
regions of adjacent elements that had similar CNE. Each region was assigned a unique 
value that represented the average CNE of segment. Segmentation was performed for each 
sample in three steps: 1) Normalization: a smoothing spline was fitted to the raw data and 
used to normalize the distribution of samples CNE; 2) Raw partition: the Vega R package 
(Morganella et al, 2010) was used to locate change-points in CNE patterns that would split 
each chromosome into discrete segments. 3) Consolidation: a t-test was used to compare 
the CNE values between consecutive regions and those with similar CNE values (p-
value<0.0001) were merged.  
 
Tumours with high stroma content, which is assumed to be diploid, could bias the CNA 
measure in cancer cells due to a masking effect. For this reason, the threshold value to 
identify a CNA from the CNE was defined as a function of the estimated proportion of stroma 
in the tumour. The stromal proportion in each sample was calculated with the ESTIMATE R 
package from gene expression data (Yoshihara et al, 2013).  A hierarchical cluster analysis 
was used to group the tumour samples into four clusters reflecting their different levels of 
stromal content, and a varying cut-off was assigned to each cluster: ±0.5 for low stromal, 
=±0.4 for medium-low stromal, ±0.3 for medium-high stromal, and ±0.2 for high stromal 
(Supplementary Figure 1). CNE that exceeded these cut-offs were considered aberrations 
(gains or losses). The proportion of altered genome was estimated for each tumour by 




Segmented data for each sample is freely available to download at the project website: 
https://www.colonomics.org/data and the raw data have been deposited at the European 
Genome-phenome Archive (EGA, http://www.ebi.ac.uk/ega/), which is hosted by the EBI, 
under accession number (EGAS00001002453). 
 
Recurrent aberrations in chromosomal segments 
The next step was the alignment of segments for all tumours to identify those with recurrent 
aberrations. The first step was to calculate minimal recurrent regions based on segmentation 
for each sample. The minimum recurrent regions were small regions with at least 5% of 
individuals with CNA. These were the smallest units of analysis used in this study. Focal 
regions with CNA were also calculated. Focal regions were defined as a set of minimal 
recurrent regions consecutive with the same CNA sign. Note that two consecutive regions 
with similar CNA may exist but defined by different tumours contributing to each minimal 
region. This may dilute further associations analysed at this level of aggregation. 
 
Focal regions were analysed with the GAIA package (Morganella et al, 2011; Yuan et al, 
2012), that allowed using different cut-offs according to the proportion of stroma. GAIA uses 
a statistical framework based on a conservative permutation test that estimates the null 
probability distribution of CNA based on the observed data. A stringent false discovery rate 
(FDR<1e-5) was used to identify focal regions. 
 
Finally, the third level of analysis considered broad events. A broad event was defined as a 
gain or loss of more than 50% of a chromosome arm. A permutation test was performed to 
detect these changes. In this test, each sample was randomly assigned a CNA status by 
chromosome and arm to define the null distribution. From that, the significance of observing 
a loss of more than 50% of a chromosome arm was calculated. 
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Molecular characterization of the tumour samples 
The CMSclassifier R package was used to classify our samples into the four CRC consensus 
molecular subtypes (CMS), using a random forest approach (Guinney et al, 2015). Tumour 
CIMP classification was derived from the methylation status in CpG islands of genes MLH1, 
RUNX3, CACNA1G, IGF2, NEUROG1, SOCS1, CRABP1 and CDKN2A. CIMP high cut-off 
was set at  >= 6/8 methylated promoters, CIMP low was defined as the presence of 1/8 to 
5/8 methylated markers, and No CIMP as 0/8 methylated markers (Ogino et al, 2007). The 
frequency of somatic mutations located in coding regions was assessed for a subset of 42 
samples with whole exome sequencing results (Sanz-Pamplona et al, 2015). Briefly, 
Genomic DNA from the set of 42 adjacent tumour paired samples was sequenced in the 
National Center of Genomic Analysis (Barcelona, Spain; CNAG) using the Illumina HiSeq- 
2000 platform. Exome capture was performed with the commercial kit Sure Select XT Human 
All Exon 50MB (Agilent). Tumour exomes were sequenced at 60X coverage and exomes 
from adjacent tissues were sequenced at 40X.  Bowtie 2.0 software was used to align 
sequences over the human reference genome. Variant calling was executed with GATK 
software, and low-quality variants (mapping quality below 30, read depth below 10 or 
frequency < 10%) were discarded. Germline variants were also removed, that is, variants 
that were present in normal adjacent paired sequence for each tumour and variants reported 
in the 1000G project. Finally, variants were annotated using the SeattleSeq Variant 




Association of CNA with clinical and molecular features and prognosis 
Non-parametric tests were used to assess the association between clinical or molecular 
features and the proportion of altered genome or minimal recurrent regions. Separate 
analyses for gains and losses were also performed.  
 
The Kaplan-Meier method was used to estimate disease free survival curves for each CNA 
state in a specific region. A total of 21 progression events had been observed in the sample 
with a minimum follow-up of three years (median 5 years). Multivariate proportional hazards 
models were used to assess CNA gains and losses as independent prognostic predictors, 
adjusted for age, sex, tumour location and the proportion of stroma. Only minimal recurrent 
regions were analysed. False discovery rate (FDR) was used to control for multiple testing in 
all analyses when minimal recurrent regions were explored. 
 
Association of CNA with gene expression changes 
Gene expression data, assessed by Affymetrix Human Genome U219 expression array has 
been previously analysed (Sanz-Pamplona et al, 2014). A unique expression value for each 
gene was estimated from multiple probes using the first principal component to capture 
maximal variability among probes. The analyses were focused on gene expression changes 
between tumour and paired adjacent normal. Thus, gene expression differences were 
analysed in relation to CNA status (loss, diploid, gain) with linear models, adjusted for age, 
sex, tumour location and stromal content. Also, partial Pearson correlation was calculated to 
assess adjusted correlations between the quantitative CNE at each region and gene 
expression changes. These analyses were restricted to 14,654 genes (out of 18,902 
annotated in the microarray) that had enough variability among samples (standard 
deviation>0.2). Two analyses (cis and trans) were performed. The former only interrogated 
genes located within each minimum recurrent region (FDR<0.05). The later assessed 
associations of all CNA with all genes, except for genes located in chromosomes X and Y, 
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and Bonferroni method was used to adjust for multiple comparisons. These analyses were 
replicated using TCGA data. 
 
Functional analysis 
A functional analysis was performed to characterise the list of genes showing significant 
associations with CNA. The Sigora R package was used, which focuses on genes or gene-
pairs that are (as a combination) specific to a single pathway (Foroushani et al, 2013). This 
analysis was restricted to genes with a strong association to CNA (FDR<0.05 and r2>0.33). 
Also, transcription factor (TF) enrichment was assessed using Fisher's exact test. 
 
RESULTS 
Proportion of altered genome. Correlation with clinical and molecular characteristics 
CNA events were detected in all samples, with a range of altered genome between 0.04 and 
26.6% (Figure 1A). Despite a homogeneous group of MSS stage II tumours were analysed, 
high variability among samples was observed. Interestingly, 10% of the tumours had less 
than 0.1% of the genome altered. A more detailed analysis, dividing CNA between gains and 
losses, revealed tumours that essentially only showed either gains or losses. The proportion 
of gained genome ranged between 0.007 and 10.4% (Figure 1B) whereas the proportion of 
lost genome ranged between 0.02 and 16.9% (Figure 1C). The proportion of altered genome 
was independent of age, sex, site location, progression, CIMP, consensus molecular subtype 
(CMS) and stromal infiltration (Table 1). The latter is not strange, since the proportion of 
altered genome at each tumour was adjusted by the proportion of stroma. However, a 
significant positive correlation was observed between the number of somatic mutations and 
total CNA (Spearman r=0.42, P=0.006) (Supplementary Figure 2). This association, which 
analysis was restricted to the 42 samples with whole-exome sequencing available, was 
weaker and no longer significant when gains and losses were analysed separately.  
 
Minimal recurrent regions. Correlation with clinical and molecular characteristics 
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A total of 26,423 segments with CNA (10,777 gains and 15,646 losses) were identified. The 
median number of altered segments per tumour was 53 gains, and 118 losses. These 
segments were transformed into 13,279 minimal recurrent regions (MRR), defined as CNA 
segments shared by at least 5 samples (5%) (Supplementary Table 2). Figure 2 shows the 
chromosomal distribution and frequency of the MRR (both gains and losses). It should be 
noted that 54% of these regions were located in recurrent regions already described in CRC 
(recurrent gains in chromosome arms 7p, 8q, 13q and 20, and recurrent losses in 8p, 17p 
and 18). Interestingly, 116 of these MRR were shared by more than 50% of the samples 
(Table 2 shows a summary of these regions). Only three of these regions included genes: 
GSTM1 in 1p13.3, SIRPB1 in 20p13 and ADAM5/ADAM3A in 8p11. The median number of 
samples per MRR was 8 (inter-quartile range 6 to 66). This small number of affected 
samples at each segment limited the power to detect associations with clinical variables. 
Indeed, no relevant association between MRR and any clinical characteristic was found 
(FDR>0.05). The association of all MRR with prognosis was also evaluated. After correction 
for multiple testing (FDR<0.05), only one region in 1p36.33 (chr1:1,627,906-1,628,405) was 
found to be statistically associated with disease free survival (P=0.00002). Tumours losing 
these region (n=6) showed poor prognosis in comparison with diploid ones (Supplementary  
Figure 3). Gene CDK11B is located within this region.  
 
Minimal recurrent regions. Correlation with gene expression  
CIS analysis. Only one third (4,292/13,279) of the MRR contained genes. Some large genes 
were included in more than one region. The linear models for the 2,168 genes included in 
such regions revealed that 785 of them (36.2% in 545 MRR) showed a significant 
relationship between the differences of expression and the CNA state at FDR<0.05 
(Supplementary Table 3). The median of the partial Pearson correlation coefficient between 
the differences of expression and CNE of these 785 genes was of 0.54 (inter-quartile range 
0.20 to 0.81), indicating that CNA explained a large fraction of the variability in gene 
expression changes between normal and tumour tissues. To note, potential stromal 
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contamination was considered in these analyses by adjusting each test for the stromal 
content of each sample.  Interestingly, 64 out of the 785 differentially expressed genes 
showed a partial correlation with CNE higher than 0.7 (more that 50% of variance explained; 
see some examples in Figure 3A-D).  
 
As expected, these genes were mainly located on chromosomes 6, 7, 8, 13, 17, 18 and 20, 
because these are the region’s most often showing CNA (Table 3 and Figure 3E). Also 
unsurprisingly, CNA gains were associated with higher gene expression and CNA losses 
were associated with lower gene expression levels. This happened in 236 genes located in 
gained regions and 30 genes located in lost regions, respectively . Also, the expression of 
genes located in regions in which both losses and gains had been observed (n=266) showed 
a good correlation with the quantitative CNE in each tumour, which can be interpreted as 
proportional to the average number of DNA copies. There were 117 MRR in which more than 
one gene showed significant changes in gene expression (20.6% of 567 MRR with >1 gene). 
Reinforcing the idea that copy number alterations are associated with changes in gene 
expression, 78% (92 of 117) of these regions showed half or more of the genes with altered 
expression. Specifically, 38 of them (32%) were MRR in which all included genes had 
consistent significant changes in expression.  
 
A functional analysis was performed with the 325 genes whose changes in expression were 
strongly associated to CNA (FDR<0.05 and r2>0.33). A significant enrichment was identified 
in “Colorectal cancer pathway”. This analysis also identified a significant enrichment of 
pathways related to “RNA degradation”, “Endocytosis”, “Basal transcription factors” or 
“Glycerophospholipid biosynthesis”; among others (Supplementary Table 4 and 
Supplementary Table 5). 
 
Trans analysis. Under the hypothesis that CNA could also have long distance effects (trans) 
on gene expression, due to regulatory effects, the association between CNA and gene 
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expression changes of all annotated genes was evaluated. This analysis explored 
15,225,697 relationships (the expression of 14,654 variable genes and 13,279 MRR; cis 
relationships previously analysed were excluded). Of them, only 191 were significant after 
Bonferroni correction (P<3.3e-9), involving 42 genes and 168 MRR (Figure 3E). All 
relationships were between genes and regions located in different chromosomes. 
Unexpectedly, 105 out of the 168 MRR (62.5%) did not contain genes, pointing to regulatory 
elements different from transcription factor activity. The remaining CNA regions (n=63) 
included 53 genes. We tested if these genes were predominantly transcription factors, but 
only 4 of them (GATA3, ST18, PRDM6, ZNF641) had this function, while we expected 10% 
by chance alone (Supplementary Table 6).   
 
Focal regions and broad events. Correlation with clinical and molecular 
characteristics 
Larger focal regions were identified from specific MRR, defined as consecutive minimal 
recurrent regions with the same CNA status (but possibly different quantitative CNE value). If 
one of these regions involved more than 50% of a chromosome arm, it was defined as a 
broad event. 
 
From 13,279 MRR, 353 focal regions were found (97 focal gains and 256 focal losses; Figure 
3E; Supplementary Table 7). The median number of samples with some aberration in these 
focal regions was 11 (inter-quartile range 8 to 14). The focal regions represented 12.5% of 
the altered genome (9.8% in lost focal regions, 2.7% in gained focal regions). These focal 
regions were enriched in genes, since 26% of the total number of human genes was in these 
CNA regions (16% in lost focal regions, 10% in gained focal regions). However, no significant 
associations were found between the average CNE in these focal regions and any of the 
clinical characteristics explored, including prognosis. 
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Five recurrent broad regions were identified: gains in 8q (6% of the samples), 13q (7% of the 
samples), 20p (6% of the samples) and 20q (24% of the samples), and losses in 8p (7% of 
the samples). No significant association between recurrent broad CNA and clinical 
characteristics or prognosis was found, except for gains in 20q, which were related to the 
number of somatic mutations (P=0.00006). Other classically altered regions in CRC were 
also detected, but at lower frequency: 7p gain (n=4), 17p loss (n=4), and 18q loss (n=3). 
Indeed, if less astringent criteria were used to detect broad regions, more altered tumours 




Validation in TCGA data 
To assess the consistency of our findings, a validation was performed using the TCGA 
dataset comprising 222 CRC tumours. To ensure a comparable data, the same pipeline of 
analysis used in our samples was followed starting from the raw TCGA data. In agreement 
with our results, the range of altered genome was 0.038 to 28.1% (0.004-12.1% gains and 
0.025-22.5% losses).  Unexpectedly, the proportion of altered genome in the TCGA showed 
a significant negative association with the number of somatic mutations (Spearman r= -0.15, 
P=0.03). Nevertheless, when only MSS samples were considered, this negative correlation 
changed and a non-significant positive correlation between the number of mutations and the 
proportion of lost genome emerged (Spearman r=0.14, P=0.08). This change in correlation 
derives from the fact that MSI tumours are hyper-mutated and usually diploid. Interestingly, a 
strong association between CMS and the proportion of altered genome was found in TCGA 
data. Subtypes CMS2 and CMS4 accumulated higher levels of chromosomal alterations than 
CMS1 and CMS3 (Supplementary Figure 4).  
A total of 8771 MRR (66% of 13279) were validated in TCGA samples, and the agreement 
was very high for MRR altered in more than 50% of the samples (Table 2). 4105 MRR were 
identified in TCGA that we had not previously observed in our data. If only stage II and III 
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MSS tumours were considered, the percentage of MRR validated in TCGA increased to 69% 
(n=51) and 68% (n=44) respectively. Finally, when comparing samples from different stages 
in TCGA dataset, 72% of MRR from stage II tumours were found in stage III tumours.  
 
Regarding the association with gene expression, it should be noted that the TGCA dataset 
only analysed 22 normal tissues, thus, the tumour-normal changes have been estimated 
respect to the average expression of these normal in an unpaired analysis. Also, only 631 
out of the 785 significant genes were found in the TCGA validation dataset. For this subset, 
79% (496 genes) of our gene expression-CNA associations were replicated, thus confirming 
that expression levels of such genes were in part explained by CNA in colon cancer (Table 3, 
Supplementary Table 3).  
 
The trans validation was performed in 127 out of the 191 associations because 19 genes and 
45 MRR were not found in the TCGA. From these, only 64 relationships (50%) were 
confirmed in the TCGA dataset, which indicated that some of our findings could be spurious 
even though we used Bonferroni correction to protect from false positive findings. 
Concerning focal and broad events, 51% of the focal regions were validated. Surprisingly, 
almost all were lost regions. Only 10 out of 97 focal gained regions were validated and all 




This comprehensive analysis confirms that CNA are frequent in MSS colon tumours, and 
probably induce relevant changes in gene expression that alter key cancer pathways. Even 
though all analysed samples were MSS, stage II colon tumours, a high heterogeneity in CNA 
among them has been observed, both in the percentage of altered genome and the location 
of the CNA.  
 
The percentage of altered genome ranged from 0.04 to 26.6% (mean 2.6%). This percentage, 
validated in TCGA data when the same methodology was used to define CNA, is lower than 
the reported in previous studies (Brosens et al, 2011; Trautmann et al, 2006; Xie et al, 2012). 
A probable reason is the rigorous cut-off used in our analysis, selected in such a way to 
reduce the number of false positive CNA that could attenuate the associations with gene 
expression. However, the frequency of recurrent CNA regions found in our study is 
consistent with previous reports, with gains in chromosomes 7, 8, 13, and 20, and losses in 
chromosomes 8, 17 and 18 (Ashktorab et al, 2010; Brosens et al, 2011; Tsafrir et al, 2006; 
Xie et al, 2012). 
 
In this study we have paid special attention to the stromal content of tumours. An initial 
analysis that used a fixed cut-off (±0.4) for all samples revealed a strong association 
between CNA and the proportion of stroma on the tumours. Specifically, tumours with 
molecular subtype CMS4, that are characterized by high stromal content (Calon et al, 2015; 
Isella et al, 2015), also showed a reduced frequency of CNA. Therefore, and since stromal 
cells are diploid, we thought that this result could be a biased estimation of CNA in tumours 
with high stromal content due to a dilution effect. Moreover, since other studies have 
described and association of CNA with poor prognosis (Andersen et al, 2011; Kurashina et al, 
2008; Orsetti et al, 2014), it seemed paradoxical that the CMS4 subtype that has poor 
prognosis was the less altered subtype. Based on this observation, we adjusted the cut-off to 
define a CNA as a function of the stromal content of the sample. After this correction, which 
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we consider less biased, no significant associations were observed between CNA and 
stromal infiltration. Though not statistically significant, differences were observed per 
molecular subtypes. CNA were more frequent in CMS4 and CMS2 tumours than in CMS1 
and CMS3 (Supplementary Figure 5). In the analysis of the TCGA data we found a 
statistically significant CNA enrichment in CMS2 and CMS4 tumours. This result agrees with 
the reported in the study describing the molecular characteristics of CRC consensus 
molecular subtypes (Guinney et al, 2015). To note, the subtype CMS4, that had the least 
CNA when stromal component was not considered, emerged as the subtype with more CNA 
changes when adjusting for stromal content. This observation should be taken into account 
when interpreting the differences in CNA among tumours with diverse proportion of stroma in 
studies that have not adjusted this effect. 
 
Most MRR identified in our tumours were validated in the TCGA dataset, confirming the 
validity of our analysis. Furthermore, this percentage was high when only MSS stage II 
tumours were used for validation purposes. Regarding focal regions, it is interesting to note 
that almost all lost regions were validated in TCGA data whereas only 10% of gains were 
validated. This result suggests that a higher heterogeneity in gained events across patients 
exists whereas lost events are prone to be more recurrent. Also, all described broad events 
were validated in TCGA data, confirming their validity. 
 
Aberrations in copy number are relevant for the consequences in gene dosage that may 
produce. This can have a direct effect on the protein levels of genes located in regions with 
CNA or mediated through modifications in regulatory elements. As expected, we have 
observed that a large fraction of expression changes in colon tumours can be explained by 
changes in CNA in the regions where these genes are located. Also, when a region contains 
multiple genes, most of them change their level of expression in a similar pattern. 
Nevertheless, though frequent, this is not a general mechanism of gene expression alteration 
in tumours, since not all genes located in CNA regions change their levels of expression 
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between normal and tumour samples. Indeed, almost 15% of genes were located in CNA 
regions but only 36% of them changed their level of expression between normal and tumour 
tissues in a way that might be causal. As expected, most expression changes directly 
followed the change in gene dosage (though some non-significant exceptions have been 
observed, possibly due to multiple comparisons). Indeed, this relation has been widely 
described in CRC (Tsafrir et al, 2006; Sillars-Hardebol et al, 2012; Wang et al, 2016).  
 
Gene expression regulation is complex. In addition to these direct relationships, trans 
associations among CNA and gene expression were also found. We hypothesized that 
transcription factors located in CNA regions could explain changes in level of expression of 
genes located in distant regions of the genome. However, only 3% of such genes are known 
transcription factors (and we expected 10%). What is more, 105 out of 168 CNA regions 
implicated in trans relationship did not contain genes, thus alternative regulation mechanisms, 
possibly involving enhancers, methylation or non-coding RNAs must be involved in these 
long distance effects of CNA in gene expression changes. It is reassuring that most cis 
(79%) and some trans (50%) relationships were validated using TCGA public data. 
 
We also assessed the association of CNA with clinical and molecular parameters. We found 
that tumours with higher number of CNA also exhibited higher number of somatic mutations 
(though this association was restricted to 42 tumours with exome data). Since only MSS 
tumours have been included in this analysis, we could hypothesize that the inverse 
relationship between CNA and mutational load previously described only emerged when 
MSS tumours were compared with hyper mutant MSI tumours. Indeed, this inverse 
relationship was observed in the TCGA validation dataset, which included MSI tumours. 
When only MSS tumours were considered, in line with our results, the trend is towards a 
positive correlation of aberrations (CNA and somatic mutations). Interestingly, these CNA are 
likely to be segment losses, which might be related to a requirement of double hit for many 
mutations to be active. 
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Specific CNA have been previously suggested as prognostic biomarkers (Brosens et al, 
2011; Wang et al, 2016; Zhang et al, 2015). In our data, we have only found one region in 
1p36.33 significantly associated with prognosis when multiple comparisons were considered. 
Tumours with this region lost showed worse prognosis than diploid tumours. This region 
contains CDK11B gene, which encodes for a cyclin-dependent kinase that plays multiple 
roles in cell cycle progression and apoptosis regulation. Thus, we hypothesize that in a 
subset of colon tumours CDK11B could act as a tumour suppressor gene. However, due to 
the small number of cancer recurrence events in our study (21 out of 99 patients) we cannot 
exclude the possibility that this region was associated with prognosis just by chance.  This 
result could not be validated in TCGA data because the follow-up information of the 
individuals has poor quality, so it deserves further study. 
 
Although originally developed to assess genetic diversity, genotyping arrays have emerged 
as a useful technology to identify regions with CNA. It is particularly important to highlight the 
high rates of false positive focal regions that can result by using these high-throughput 
techniques. For this reason, we have used a conservative and variable threshold according 
to the proportion of stroma for each sample. The selection of a method to call CNA regions 
represents a great challenge because there are many available, usually with little 
experimental validation, and the results are not necessarily consistent. So far, little work has 
been deserved to compare results obtained through different methods among them (Koike et 
al, 2011; Morganella et al, 2010). After exploring diverse software tools, we selected a 
method that provided more precise results when focal CNA regions were visually inspected. 
Also, the results obtained regarding the frequency and chromosomal distribution of CNA 
were similar to previously reported for CRC using different methods, thus reassuring the 
validity of our approach (Morganella et al, 2010; Morganella et al, 2011; Rueda & Diaz-
Uriarte, 2010). Smaller regions with CNA observed in multiple samples help to better identify 
potential causal genes behind the observed associations. Larger focal regions, as identified 
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by the GAIA software, paradoxically decrease the power to detect associations with clinical 
variables, because the enlarged region usually combines samples with heterogeneous CNA. 
 
In conclusion, this comprehensive analysis has shown that CNA are highly frequent and 
heterogeneous events in MSS stage II colon tumours. The variation of gene expression 
between tumour tissues and their paired adjacent normal mucosa was explained by CNA on 
36% of the genes affected by this type of aberrations, and genes often altered belong to key 
cancer pathways. These altered genes by CNA represent 5% of the total number of genes 
expressed in the colon. 
 
Also, from a methodological perspective, we have found that the proportion of tumour stroma 
may bias the estimation of CNA. To avoid this effect, an adjusted cut-off definition 
proportional to the estimated stromal content produced more accurate results. 
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FIGURE LEGENDS 
Figure 1: Distribution of clinical characteristics according to the proportion of altered 
genome   
The histogram represents the proportion of altered genome by sample (purple: gains, red: 
losses). In the lower part, the clinical characteristics of the individuals are represented: sex 
(blue: female, red: male), age (sliding scale from white: minimum to brown: maximum), 
tumour location (light green: left, dark green: right), development of metastases (light pink: no, 
dark pink: yes), CIMP (white: no, green: CIMP low, blue: CIMP high), number of mutations 
(sliding scale from white: 0 to dark blue: maximum), proportion of stroma (light green: low, 
dark green: high), molecular subtype (yellow: CMS1, blue: CMS2, plink: CMS3, green: 
CMS4). A. All CNA. B. Gains. C. Losses. 
 
Figure 2: Frequency of CNA by chromosome  
Each graph represents a chromosome with chromosomal position in the X-axis. Y-axis 
displays the percentage of tumour with gains (>0, purple) or losses (<0, red). The height of 
the bar is proportional to the number of samples showing the CNA change.  Dashed lines 
represent the frequency (black: 5%, green: 20% red: 50%).  
 
Figure 3: Relationship between gene expression and CNA  
A-D: Boxplots showing examples of gene expression changes based on CNA levels. 
Spearman correlation and FDR p value are shown. “L” indicates number of individuals losing 
the region whereas “G” indicates number of individuals gaining the region. E. Circus plot of 
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CNA recurrent regions and their association with changes in gene expression.  Outer circle 
shows ideograms of the chromosomes. Inner circles show, in order, focal regions (gains in 
purple, losses in red), broad events, and genomic location of significant associations 
between CNA and the difference in expression between tumour and adjacent normal (blue) 
in cis analysis. The central arcs indicate genomic locations with significant trans associations 
between CNA and changes of gene expression. 
 
SUPPLEMENTARY FILES 
Supplementary Table 1: Baseline characteristics of tumours of CLX and TCGA datasets. 
Supplementary Table 2: List of minimal recurrent region (MRR) in CLX and TCGA datasets. 
Supplementary Table 3: List of 785 significant genes obtained in the cis analysis. 
Supplementary Table 4: Significant pathways in which CNA genes are involved. 
Supplementary Table 5: Categorization of CNA genes into significant pathways. 
Supplementary Table 6: List of transcription factors identified in the trans analysis. 
Supplementary Table 7: Number of recurrent focal regions in all samples by chromosome. 
Supplementary Table 8: Number of individuals altered by percentage of altered 
chromosomal arm. 
 
Supplementary Figure 1: Steps to calculate cut-off values based on the estimated 
stroma. The threshold value to define a CNA was defined variable for each tumour, as a 
function of its estimated stromal proportion. Tumours with a lower proportion of stroma were 
assigned a higher cut-off of the CNE; and tumours with a higher proportion of stroma were 
assigned a lower cut-off of the CNE. A hierarchical cluster analysis was used to group the 
tumour samples into four clusters reflecting their different levels of stromal content. 
Dendrograms generated from the estimate of the stromal proportion were shown in A (CLX 
dataset) and B (TCGA dataset). The cut-off value to call a CNA was determined by the 
histogram of CNE, such that both the left and right tail areas cover 5, 10, 20 and 30 percent 
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of the whole distribution. The CNE values of each segment were represented on the Y axis. 
The distribution of the different quartiles of the read depth signal was represented by 
boxplots in CLX dataset (C) and TCGA dataset (D). A log2 ratio cut-off was assigned to each 
stroma cluster: very low stromal (cut-off=±0.5), relatively low stromal (cut-off=±0.4), relatively 
high stromal (cut-off=±0.3), and high stromal (cut-off=±0.2). The estimated stromal proportion 
was represented on the Y axis. The cut-off of the CNE were represented in the different 
boxes in CLX dataset (E) and TCGA dataset (F). 
 
Supplementary Figure 2:  Relationship between the proportion of altered genome and the 
number of mutations in CLX dataset. The p-values for the Kruskal-Wallis test are shown for 
all CNA (A), gains (B) and losses (C). 
 
Supplementary Figure 3: Disease-free survival curves for region in 1p36.33 according to 
CNA in CXL dataset. Cox p value is showed. 
 
Supplementary Figure 4: Relationship between the proportion of altered genome and the 
molecular subtype in TCGA dataset. The p-values for the Kruskal-Wallis test are shown for 
all CNA (A), gains (B) and losses (C). 
 
Supplementary Figure 5: Boxplots showing proportion of altered genome according to 
tumour stromal content (low/high) and consensus molecular subtype (CMS1-4) when fixed 
and variable cut-offs were used to define CNA in CLX dataset. (A) Relationship between the 
proportion of altered genome and tumour stromal content with a fixed cut-off point of CNA. 
(B) Relationship between the proportion of altered genome and tumour stromal content with 
a variable cut-off point of CNA. (C) Relationship between the proportion of altered genome 
and CMS with a fixed cut-off point of CNA. (D) Relationship between the proportion of altered 





Table 1: Association between the percentage of altered genome and clinical characteristics 
 
  Total Losses Gains 
  Median* P Median* P Median* P 








0.18 [65-72) 1.06 0.16 0.73[72-78) 1.92 0.29 1.33
>=78 0.63 0.15 0.26
Spearman -0.08 0.42 0.008 0.94 -0.18 0.07 
Site Left 1.19 0.24 0.18 0.55 0.84 0.14 Right 0.84 0.16 0.32
CIMP 





0.78 CIMP Low 1.05 0.15 0.56








0.03 CMS2 1.24 0.18 0.82 CMS3 0.39 0.14 0.3 










[60-120) 0.87 0.15 0.78 
[120-150) 1.04 0.15 0.74 
>=150 5.48 2.1 1.76 
Spearman 0.42 0.006 0.3 0.06 0.26 0.09 
Proportion 
of stroma 
Low 0.87 0.07 0.15 0.06 0.4 0.02 High 1.69 0.22 1.33 
Spearman 0.25 0.02 0.24 0.02 0.26 0.01 
Progression No 1.02 0.73 0.2 0.48 0.59 0.67 Yes 0.78 0.13 0.43
* Median percentage of altered genome. Except for rows with Spearman in which r is shown 
P values are unadjusted for multiple comparisons. 
 
Table 2: Summary of minimal recurrent regions (MRR) with more than 50% of the samples altered of the CLX dataset 
 




% median samples 
altered in CLX 
Number of MRR 
contained in TCGA 
% samples altered in 
TCGA 
Genes included in the 
region 
1 1p31.1 72771355 72779078 5 52 4 54  
1 1p13.3 110233315 110234397 3 51 3 63 GSTM1 
1 1q21.3 152555783 152586104 10 51 10 65  
3 3q29 192880714 192882890 5 56 6 74  
4 4p16.1 10214160 10234595 16 63 27 73  
5 5p11 46271918 46273489 2 52 3 55  
5 5q11.2 57326015 57333502 16 59 22 52  
8 8p11.22 39246663 39386952 22 64 25 47 ADAM5, ADAM3A 
8 8q23.2 112295069 112295247 2 56 3 67  
12 12p13.31 9637897 9690962 5 53 7 61  
13 13q21.31 72479535 72480543 1 57 1 51  
17 17q21.2 39423091 39430518 12 58 15 46  
20 20p13 1561568 1582194 17 54 20 51 SIRRPB1 
 
 
Table 3: Chromosomal distribution of genes related to CNA and validation in TCGA data 
 
 







Validation in MSS and 
stage II in TCGA data 
1 1542 44 (2.85 % ) 2 1 0
2 1013 23 (2.27 % ) 1 0 0 
3 847 49 (5.8 % ) 3 0 0 
4 606 20 (3.3 % ) 1 0 0 
5 680 64 (9.4 % ) 12 0 0
6 812 105 (13 % ) 30 1 0 
7 733 150 (20.5 % ) 18 0 10 
8 528 518 (98.1 % ) 282 220 134
9 599 27 (4.5 % ) 4 3 1
10 579 35 (6.04 % ) 3 0 0 
11 896 36 (4.02 % ) 1 0 0 
12 779 39 (5 % ) 17 5 5
13 268 268 (100 % ) 115 91 74 
14 496 17 (3.43 % ) 0 0 0 
15 487 17 (3.49 % ) 1 0 0 
16 679 32 (4.71 % ) 2 1 0 
17 921 142 (15.42 % ) 36 5 1 
18 210 97 (46.19 % ) 35 5 2 
19 1033 30 (2.9 % ) 0 0 0
20 416 412 (99.04 % ) 221 164 135 
21 156 17 (10.9 % ) 0 0 0 
22 374 26 (6.9 % ) 1 0 1
Total 14654 2168 (14.8 % ) 785 488 363
 
* FDR was used to identify significant associations 
 
